ATHA250117C5000
- 0.05
- 0.000.00%
Athira Newsroom
Athira Pharma Insider Ups Holding By 111% During Year
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects Of ATH-1105 In Models Of ALS At Motor Neurone Disease Association's International Symposium On ALS/MND
Athena Gold Upsizes Private Placement From C$1M to up to C$1.25M
Athira Pharma's Regulatory Compliance Challenges Threaten Drug Development Pipeline
Althira Pharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results.
Express News | Althira Pharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results
JMP Securities Maintains Athira(ATHA.US) With Hold Rating
Athira Pharma Reports Q3 2024 Financial Results
JMP Securities Keeps Their Hold Rating on Athira Pharma (ATHA)
Athira | 10-Q: Q3 2024 Earnings Report
Athira | 8-K: Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Express News | Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Express News | Athira Pharma Q3 EPS USD -0.75
Express News | Athira Pharma Q3 Operating Income USD -29.621 Million
Express News | Athira Pharma Q3 Net Income USD -28.741 Million
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Express News | Phoenix Motor shares surge 31% after reporting a record $12 million in revenue for Q2.
12 Health Care Stocks Moving In Thursday's After-Market Session
Athira Pharma to Present Results From Phase 2/3 LIFT-AD Trial
Express News | Athira Pharma Inc - Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing